Literature DB >> 20333868

Serum osteoprotegrin (OPG) and receptor activator of nuclear factor kappaB (RANKL) in healthy children and adolescents.

A Wasilewska1, A A Rybi-Szuminska, W Zoch-Zwierz.   

Abstract

UNLABELLED: Most metabolic bone diseases are characterized by a disturbance in bone resorption, therefore biochemical markers concerning this process are of special interest. Recent investigations in bone biology identified the RANKL/ RANK/OPG system, the set of cytokines or cytokine receptors belonging to the tumor necrosis factor (TNF) family that are required for control of bone modeling and remodeling. The imbalance between OPG and RANKL was found not only in pathology of bone, but also in the control of the immune and vascular systems. However, clinical application of new bone markers in children may be difficult due to lack of reference data in relation to age, sex and physiological development. AIM: To investigate the relationship of serum concentrations of OPG, RANKL and OPG/RANKL ratio in relation to age, sex and parameters of physical development in healthy children and adolescents. CHILDREN AND METHODS: The study was performed on a group of 70 healthy children and adolescents, divided into subgroups according to sex and age. OPG and sRANKL serum concentrations were determined using ELISA.
RESULTS: Serum OPG did not differ between boys and girls or younger and older children. There was no correlation between OPG level and height, weight and BMI percentiles. The level of sRANKL was 3 times higher in males than in females (p < 0.01) and almost 3 times higher in older than younger children (p < 0.01). There was a positive correlation between sRANKL concentration and body weight percentile (r = 0.268, p < 0.05). There was no correlation between serum OPG and sRANKL levels.
CONCLUSION: In healthy children and adolescents the serum level of OPG is not influenced by age, sex or parameters of physical development, in contrast to sRANKL and sRANKL/OPG ratio, which are dependent on these factors. Age and sex reference data should be established.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20333868     DOI: 10.1515/jpem.2009.22.12.1099

Source DB:  PubMed          Journal:  J Pediatr Endocrinol Metab        ISSN: 0334-018X            Impact factor:   1.634


  6 in total

1.  In peripubertal girls, artistic gymnastics improves areal bone mineral density and femoral bone geometry without affecting serum OPG/RANKL levels.

Authors:  L Maïmoun; O Coste; D Mariano-Goulart; F Galtier; T Mura; P Philibert; K Briot; F Paris; C Sultan
Journal:  Osteoporos Int       Date:  2011-02-26       Impact factor: 4.507

2.  Serum RANKL, osteoprotegerin (OPG), and RANKL/OPG ratio in nephrotic children.

Authors:  Anna Wasilewska; Agnieszka Rybi-Szuminska; Walentyna Zoch-Zwierz
Journal:  Pediatr Nephrol       Date:  2010-07-04       Impact factor: 3.714

3.  Assessment of bone metabolism and biomechanical properties of the femur, following treatment with anastrozole and letrozole in an experimental model of menopause.

Authors:  Ioannis Boutas; Vasilios Pergialiotis; Nicolaos Salakos; Laskarina-Maria Korou; Athanasios Mitousoudis; Emmanouil Kalampokas; Efthimios Deligeoroglou; Odysseas Gregoriou; Despina N Perrea; George Creatsas; Stavros Kourkoulis
Journal:  Oncol Lett       Date:  2017-07-18       Impact factor: 2.967

4.  Decreased level of soluble receptor activator of nuclear factor-κβ ligand (sRANKL) in overweight and obese children.

Authors:  Michał Erazmus; Małgorzata Rumińska; Ewelina Witkowska-Sędek; Anna M Kucharska; Anna Stelmaszczyk-Emmel; Anna Majcher; Beata Pyrżak
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-19       Impact factor: 6.055

5.  Effects of salubrinal on development of osteoclasts and osteoblasts from bone marrow-derived cells.

Authors:  Hiroki Yokota; Kazunori Hamamura; Andy Chen; Todd R Dodge; Nancy Tanjung; Aysan Abedinpoor; Ping Zhang
Journal:  BMC Musculoskelet Disord       Date:  2013-07-01       Impact factor: 2.362

6.  Osteoprotegerin, Soluble Receptor Activator of Nuclear Factor- κ B Ligand, and Subclinical Atherosclerosis in Children and Adolescents with Type 1 Diabetes Mellitus.

Authors:  Irene Lambrinoudaki; Emmanouil Tsouvalas; Marina Vakaki; George Kaparos; Kimon Stamatelopoulos; Areti Augoulea; Paraskevi Pliatsika; Andreas Alexandrou; Maria Creatsa; Kyriaki Karavanaki
Journal:  Int J Endocrinol       Date:  2013-10-30       Impact factor: 3.257

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.